An allosteric switch for pro-HGF/Met signaling using zymogen activator peptides

Nature Chemical Biology

Volumn 10, Issue 7, 2014, Pages 567-573

  Landgraf, Kyle E ^a,b   Steffek, Micah ^a,c   Quan, Clifford ^a   Tom, Jeffrey ^a   Yu, Christine ^a   Santell, Lydia ^a   Maun, Henry R ^a   Eigenbrot, Charles ^a   Lazarus, Robert A ^a  

^a GENENTECH INC   (United States)

^b AvidBiotics Corporation   (United States)

^c Novartis Vaccines and Diagnostics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME PRECURSOR; PROTEIN C; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; SERINE; SERINE PROTEINASE;

ALLOSTERISM; ARTICLE; BINDING AFFINITY; CONFORMATIONAL TRANSITION; ENZYME ACTIVATION; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN STRUCTURE; SIGNAL TRANSDUCTION;

ALLOSTERIC REGULATION; ALLOSTERIC SITE; AMINO ACID SEQUENCE; ANIMALS; CATALYTIC DOMAIN; CELL MOVEMENT; CELL SURVIVAL; CHO CELLS; CRICETULUS; GENE EXPRESSION REGULATION; HEPATOCYTE GROWTH FACTOR; HUMANS; MODELS, MOLECULAR; MOLECULAR MIMICRY; MOLECULAR SEQUENCE DATA; PEPTIDE LIBRARY; PEPTIDES; PROTEIN BINDING; PROTEIN C; PROTEIN ENGINEERING; PROTEIN PRECURSORS; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MET; SIGNAL TRANSDUCTION;

EID: 84902847958     PISSN: 15524450     EISSN: 15524469     Source Type: Journal    
DOI: 10.1038/nchembio.1533     Document Type: Article

References (60)

1. Nakamura, T. et al. Molecular cloning and expression of human hepatocyte growth factor. Nature 342, 440-443 (1989).
2. Stoker, M., Gherardi, E., Perryman, M. & Gray, J. Scatter factor is a fibroblast-derived modulator of epithelial cell mobility. Nature 327, 239-242 (1987).
3. Crestani, B. et al. Hepatocyte growth factor and lung fibrosis. Proc. Am. Thorac. Soc. 9, 158-163 (2012).
4. Nakamura, T., Sakai, K., Nakamura, T. & Matsumoto, K. Hepatocyte growth factor twenty years on: Much more than a growth factor. J. Gastroenterol. Hepatol. 26 (suppl. 1), 188-202 (2011).
5. Jones, D.S. II, Tsai, P.C. & Cochran, J.R. Engineering hepatocyte growth factor fragments with high stability and activity as Met receptor agonists and antagonists. Proc. Natl. Acad. Sci. USA 108, 13035-13040 (2011).
6. Tolbert, W.D., Daugherty-Holtrop, J., Gherardi, E., Vande Woude, G. & Xu, H.E. Structural basis for agonism and antagonism of hepatocyte growth factor. Proc. Natl. Acad. Sci. USA 107, 13264-13269 (2010).
7. Chakraborty, S., Chopra, P., Hak, A., Dastidar, S.G. & Ray, A. Hepatocyte growth factor is an attractive target for the treatment of pulmonary fibrosis. Expert Opin. Investig. Drugs 22, 499-515 (2013).
8. Ueki, T. et al. Hepatocyte growth factor gene therapy of liver cirrhosis in rats. Nat. Med. 5, 226-230 (1999).
9. Bevan, D., Gherardi, E., Fan, T.P., Edwards, D. & Warn, R. Diverse and potent activities of HGF/SF in skin wound repair. J. Pathol. 203, 831-838 (2004).
10. Nakamura, T. et al. Myocardial protection from ischemia/reperfusion injury by endogenous and exogenous HGF. J. Clin. Invest. 106, 1511-1519 (2000).
11. Bottaro, D.P. et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 251, 802-804 (1991).
12. Comoglio, P.M., Giordano, S. & Trusolino, L. Drug development of MET inhibitors: Targeting oncogene addiction and expedience. Nat. Rev. Drug Discov. 7, 504-516 (2008).
13. Gherardi, E., Birchmeier, W., Birchmeier, C. & Vande Woude, G. Targeting MET in cancer: Rationale and progress. Nat. Rev. Cancer 12, 89-103 (2012).
14. Hartmann, G. et al. Engineered mutants of HGF/SF with reduced binding to heparan sulphate proteoglycans, decreased clearance and enhanced activity in vivo. Curr. Biol. 8, 125-134 (1998); erratum 8, R739 (1998).
15. Lyon, M., Deakin, J.A., Mizuno, K., Nakamura, T. & Gallagher, J.T. Interaction of hepatocyte growth factor with heparan sulfate. Elucidation of the major heparan sulfate structural determinants. J. Biol. Chem. 269, 11216-11223 (1994).
16. Donate, L.E. et al. Molecular evolution and domain structure of plasminogen-related growth factors (HGF/SF and HGF1/MSP). Protein Sci. 3, 2378-2394 (1994).
17. Lokker, N.A. et al. Structure-function analysis of hepatocyte growth factor: Identification of variants that lack mitogenic activity yet retain high affinity receptor binding. EMBO J. 11, 2503-2510 (1992).
18. Kirchhofer, D. et al. Structural and functional basis of the serine protease-like hepatocyte growth factor ß-chain in Met binding and signaling. J. Biol. Chem. 279, 39915-39924 (2004).
19. Bode, W. & Huber, R. Induction of the bovine trypsinogen-Trypsin transition by peptides sequentially similar to the N-Terminus of trypsin. FEBS Lett. 68, 231-236 (1976).
20. Huber, R. & Bode, W. Structural basis of the activation and action of trypsin. Acc. Chem. Res. 11, 114-122 (1978).
21. Hedstrom, L. Serine protease mechanism and specificity. Chem. Rev. 102, 4501-4524 (2002).
22. Khan, A.R. & James, M.N. Molecular mechanisms for the conversion of zymogens to active proteolytic enzymes. Protein Sci. 7, 815-836 (1998).
23. Miyazawa, K. Hepatocyte growth factor activator (HGFA): A serine protease that links tissue injury to activation of hepatocyte growth factor. FEBS J. 277, 2208-2214 (2010).
24. Kataoka, H. & Kawaguchi, M. Hepatocyte growth factor activator (HGFA): Pathophysiological functions in vivo. FEBS J. 277, 2230-2237 (2010).
25. Naka, D. et al. Activation of hepatocyte growth factor by proteolytic conversion of a single chain form to a heterodimer. J. Biol. Chem. 267, 20114-20119 (1992).
26. Lokker, N.A., Presta, L.G. & Godowski, P.J. Mutational analysis and molecular modeling of the N-Terminal kringle-containing domain of hepatocyte growth factor identifies amino acid side chains important for interaction with the c-Met receptor. Protein Eng. 7, 895-903 (1994).
27. Kirchhofer, D. et al. Utilizing the activation mechanism of serine proteases to engineer hepatocyte growth factor into a Met antagonist. Proc. Natl. Acad. Sci. USA 104, 5306-5311 (2007).
28. Peek, M., Moran, P., Mendoza, N., Wickramasinghe, D. & Kirchhofer, D. Unusual proteolytic activation of pro-hepatocyte growth factor by plasma kallikrein and coagulation factor XIa. J. Biol. Chem. 277, 47804-47809 (2002).
29. Lee, S.L., Dickson, R.B. & Lin, C.Y. Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease. J. Biol. Chem. 275, 36720-36725 (2000).
30. Kirchhofer, D. et al. Hepsin activates pro-hepatocyte growth factor and is inhibited by hepatocyte growth factor activator inhibitor-1B (HAI-1B) and HAI-2. FEBS Lett. 579, 1945-1950 (2005).
31. Stamos, J., Lazarus, R.A., Yao, X., Kirchhofer, D. & Wiesmann, C. Crystal structure of the HGF ß-chain in complex with the Sema domain of the Met receptor. EMBO J. 23, 2325-2335 (2004).
32. Kaibori, M. et al. Impairment of activation of hepatocyte growth factor precursor into its mature form in rats with liver cirrhosis. J. Surg. Res. 106, 108-114 (2002).
33. Phin, S. et al. Imbalance in the pro-hepatocyte growth factor activation system in bleomycin-induced lung fibrosis in mice. Am. J. Respir. Cell Mol. Biol. 42, 286-293 (2010).
34. Marchand-Adam, S. et al. Defect of pro-hepatocyte growth factor activation by fibroblasts in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 174, 58-66 (2006).
35. Landgraf, K.E. et al. Allosteric peptide activators of pro-hepatocyte growth factor stimulate Met signaling. J. Biol. Chem. 285, 40362-40372 (2010).
36. Bøtkjær, K.A. et al. Nonproteolytic induction of catalytic activity into the single-chain form of urokinase-Type plasminogen activator by dipeptides. Biochemistry 48, 9606-9617 (2009).
37. Hedstrom, L., Lin, T.Y. & Fast, W. Hydrophobic interactions control zymogen activation in the trypsin family of serine proteases. Biochemistry 35, 4515-4523 (1996).
38. Gao, J., Sidhu, S.S. & Wells, J.A. Two-state selection of conformation-specific antibodies. Proc. Natl. Acad. Sci. USA 106, 3071-3076 (2009).
39. Rizk, S.S. et al. Allosteric control of ligand-binding affinity using engineered conformation-specific effector proteins. Nat. Struct. Mol. Biol. 18, 437-442 (2011).
40. Martens, T. et al. A novel one-Armed anti-c-Met antibody inhibits glioblastoma growth in vivo. Clin. Cancer Res. 12, 6144-6152 (2006).
41. Benight, N.M. & Waltz, S.E. Ron receptor tyrosine kinase signaling as a therapeutic target. Expert Opin. Ther. Targets 16, 921-931 (2012).
42. Yao, H.P., Zhou, Y.Q., Zhang, R. & Wang, M.H. MSP-RON signalling in cancer: Pathogenesis and therapeutic potential. Nat. Rev. Cancer 13, 466-481 (2013).
43. Gohara, D.W. & Di Cera, E. Allostery in trypsin-like proteases suggests new therapeutic strategies. Trends Biotechnol. 29, 577-585 (2011).
44. Huntington, J.A. Thrombin plasticity. Biochim. Biophys. Acta 1824, 246-252 (2012).
45. Pozzi, N., Barranco-Medina, S., Chen, Z. & Di Cera, E. Exposure of R169 controls protein C activation and autoactivation. Blood 120, 664-670 (2012).
46. Pozzi, N. et al. Autoactivation of thrombin precursors. J. Biol. Chem. 288, 11601-11610 (2013).
47. Vogt, A.D. & Di Cera, E. Conformational selection is a dominant mechanism of ligand binding. Biochemistry 52, 5723-5729 (2013).
48. Friedrich, R. et al. Staphylocoagulase is a prototype for the mechanism of cofactor-induced zymogen activation. Nature 425, 535-539 (2003).
49. Gough, J., Karplus, K., Hughey, R. & Chothia, C. Assignment of homology to genome sequences using a library of hidden Markov models that represent all proteins of known structure. J. Mol. Biol. 313, 903-919 (2001).
50. Crooks, G.E., Hon, G., Chandonia, J.M. & Brenner, S.E. WebLogo: A sequence logo generator. Genome Res. 14, 1188-1190 (2004).
51. Tonikian, R., Zhang, Y., Boone, C. & Sidhu, S.S. Identifying specificity profiles for peptide recognition modules from phage-displayed peptide libraries. Nat. Protoc. 2, 1368-1386 (2007).
52. Otwinowski, Z. & Minor, W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276, 307-326 (1996).
53. Kabsch, W. XDS. Acta Crystallogr. D Biol. Crystallogr. 66, 125-132 (2010).
54. Winn, M.D. et al. Overview of the CCP4 suite and current developments. Acta Crystallogr. D Biol. Crystallogr. 67, 235-242 (2011).
55. McCoy, A.J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658-674 (2007).
56. Adams, P.D. et al. PHENIX: A comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr. 66, 213-221 (2010).
57. Emsley, P., Lohkamp, B., Scott, W.G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66, 486-501 (2010).
58. Murshudov, G.N., Vagin, A.A. & Dodson, E.J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. D Biol. Crystallogr. 53, 240-255 (1997).
59. Bricogne, G. et al. BUSTER version 2.11.2. (Global Phasing Ltd., Cambridge, United Kingdom, 2011).
60. The PyMOL Molecular Graphics System, Version 1.4.1, Schrödinger, LLC.